Table 2. Univariable Cox Regression Analysis of Clinicopathologic Parameters for Predicting RFS.
| Parameters | Hazard Ratio (95% CI) | P |
|---|---|---|
| Age (per year increase) | 0.999 (0.968–1.031) | 0.931 |
| Sex (male to female) | 0.810 (0.463–1.417) | 0.460 |
| Tumor size (per cm increase) | 1.133 (1.059–1.213) | < 0.001 |
| Histologic grade* | 1.933 (0.263–14.200) | 0.517 |
| 1.941 (0.255–14.742) | 0.522 | |
| Multiplicity | 2.201 (1.159–4.180) | 0.016 |
| Extrahepatic extension | 2.094 (1.236–3.548) | 0.006 |
| Vascular invasion | 1.648 (0.980–2.771) | 0.059 |
| Regional lymph node metastasis | 2.711 (1.547–4.751) | < 0.001 |
| Underlying hepatitis | 0.656 (0.375–1.147) | 0.139 |
| CA 19-9 (per U/mL increase) | 1.000 (1.000–1.000) | 0.321 |
| CEA (per ng/mL increase) | 1.021 (1.007–1.035) | 0.003 |
| AST (per IU/L increase) | 1.004 (0.999–1.010) | 0.153 |
| ALT (per IU/L increase) | 1.001 (0.998–1.005) | 0.546 |
| Bilirubin (per mg/dL increase) | 1.071 (0.895–1.282) | 0.455 |
| Albumin (per g/dL increase) | 0.656 (0.354–1.217) | 0.181 |
*Histologic grade was compared between reference variable (well differentiated) and test variables (moderately differentiated, in the first raw and poorly differentiated, in the second raw). ALT = alanine aminotransferase, AST = aspartate transaminase, CA 19-9 = carbohydrate antigen 19-9, CEA = cancer embryonic antigen, CI = confidence interval, RFS = recurrence-free survival